semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Solid Tumor Malignant Solid Tumor Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 Has at least 1 measurable lesion according to Response Evaluation in Solid Tumors (RECIST) Version 1.1 Has adequate cardiac, hematopoietic, renal and hepatic functions Has an adequate treatment washout period prior to start of study treatment Additional for Part 1 (Dose Escalation) Has a pathologically documented advanced/unresectable or metastatic head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, squamous and adenocarcinoma non-small cell lung cancer (NSCLC), bladder cancer, sarcoma, endometrial cancer, melanoma, prostate cancer, breast cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available. Additional for Part 2 (Dose Expansion) Has a pathologically documented advanced/unresectable or metastatic head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, squamous-NSCLC that is refractory to or intolerable with standard treatment, or for which no standard treatment is available. Additional or alternative indications may be added to expansion cohorts based on preliminary signals of activity in dose escalation via a protocol amendment  Has prior treatment with B7-H3 targeted agent Has prior treatment with an antibody drug conjugate that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan) Has multiple primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (New York Heart Association classes II-IV), unstable angina or serious cardiac arrhythmia Has an uncontrolled infection requiring systemic therapy Has clinically significant pulmonary compromise or requirement for supplemental oxygen Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation of the subject or evaluation of the clinical study in the opinion of the Investigator
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Healthy Diet Latina immigrant Resident of selected randomization unit (place of residence) At least one HPV unvaccinated daughter between the ages of 9 and 12
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-64.0,  Cervical Cancer HPV Infection HIV Infections Women aged 25-64 HIV diagnosis ≥ 6 months No previous diagnosis of CIN 2/3 and/or treatment for cervical dysplasia Last smear test done ≥1 year before baseline Able to speak and understand English Willing and able to provide informed consent  Suspected or known invasive cervical malignancy Currently pregnant or breast-feeding Any other condition, which, in the opinion of the Investigator, would make participation in the study unsafe or interfere with interpretation of the study outcomes
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bladder Cancer Patients with a known history of Ta HG with recurrent disease Patients referred to short-term, intensive chemoresection Patients older than 18 years  Known allergy or intolerance to Mitomycin Incontinence or small bladder capacity (< 100 mL) Previous pelvic radiation therapy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Adherence to Drug Therapy in Patients With HFrEF patients with HFrEF  Inability or refusal to give written informed consent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  HPV Infection Lesion Cervix Woman over 25 years, whether or not they have been vaccinated against HPV. 2. Able to read and understand the Patient Information Sheet and the Informed Consent form and accept the participation in the study by signing the Informed Consent form. 3. Patient who comes to a visit with a routine cytological result of ASCUS or LSIL and HPV-positive test, of at most 3 months prior to the start of treatment with Papilocare®. 4. Patient who, under that situation, undergoes a colposcopy and has a concordant result with cytology. 5. Patient who has been prescribed treatment with Papilocare® by medical decision prior to their participation in the study  Any situation / alteration / pathology, gynecological or not, which, in medical judgment, does not advise or contraindicate the use of Papilocare®. 2. Women of childbearing age who do not use effective contraceptive methods, pregnant women, suspected pregnancy, desire for the same within the next 6 months or during breastfeeding. 3. Participation in any one clinical trial at present or in the 4 weeks prior to in the study. 4. Any planned surgery that precludes correct compliance with the guideline. 5. Known allergies to any of the components of Papilocare®
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hip Osteoarthritis Surgery scheduled to undergo primary unilateral anterior total hip arthroplasty for the treatment of arthritis under the care of the Principal investigator available for follow ups postoperatively  Age <18 or > 75 Preoperative BMI ≥ 40 Revision (i.e., non-primary) THA procedures Patients who have undergone THA in contralateral hip within the past 6 months Patient is scheduled for or anticipating THA on contralateral limb within 6 months Patients with an active infection (at the time of screening through surgery, as this is a surgical contraindication) Current co-morbidities such as alcohol or drug addiction, and/or mental disorders could potentially interfere with study participation Cognitive deficit or significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting History of severe osteoporosis, metabolic bone disease, radioactive bone disease, or tumor in the bone surrounding the hip joint History of significant neurological and/or musculoskeletal disorders that may adversely affect gait after THA
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Non-Small Cell Carcinoma Stage I Lung Cancer AJCC v8 Stage IA1 Lung Cancer AJCC v8 Stage IA2 Lung Cancer AJCC v8 Stage IA3 Lung Cancer AJCC v8 Stage IB Lung Cancer AJCC v8 Stage IIA Lung Cancer AJCC v8 Patient must have histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0). Patient may have T3 disease with the of multifocal tumors and pericardial involvement Disease must have one or more of the following high-risk features Tumor diameter >= 2 cm as assessed by diagnostic computed tomography (CT) Tumor standard uptake value (SUV) max >= 6.2 as assessed by fludeoxyglucose F-18 (FDG) positron emission tomography (PET)/CT Moderately differentiated, poorly differentiated, or undifferentiated histology Patient must have undergone diagnostic chest CT with contrast (unless medically contraindicated) within 42 days prior to randomization. PET-CT may be used if the CT portion is of identical diagnostic quality to a stand-alone CT. All disease must be assessed within 42 days prior to randomization Patient must have undergone FDG PET/CT of chest within 90 days prior to randomization Patient must not have evidence of hilar or mediastinal nodal involvement. Any patient with radiographically suspicious hilar or mediastinal nodes (including features such as non-calcified nodes with a short axis diameter > 1 cm, abnormal morphology, and/or elevated FDG avidity) must undergo cytologic sampling of suspicious nodes to rule out involvement prior to randomization. Mediastinal nodal sampling for other patients is optional Patient must have undergone history and physical examination within 28 days prior to randomization Patient must be medically or surgically inoperable as documented by a board certified thoracic surgeon or multi-disciplinary tumor board consensus OR patient's unwillingness to undergo surgical resection must be clearly documented
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-44.0,  Diabetes, Gestational Menstrual Cycle Abnormal pregnant women with gestational diabetes  Patients with hypertension and pregestational diabetes mellitus Patients with rheumatologic, nephrological, and hematological diseases Presence of active infection corticosteroid use, acetylsalicylic acid, and anticoagulant use
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Women With Suspected or Confirmed Gynecological Disease Be at least 18 years of age Have capacity to understand the study Be able to provide informed consent If the patient has a recently treated cervical abnormality, she must have had a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy Have suspected or confirmed cancer of the upper genital tract and be undergoing surgery for said tumor removal  Prior hysterectomy Be pregnant or possibly pregnant Be nursing, as the device contains phthalates (plasticizers) that "have not been fully characterized and there may be concern for reproductive and developmental effects" Have an infected or inflamed cervix Have a confirmed or suspected pelvic infection Have a confirmed or suspected vaginal infection Have had recent history of uterine perforation Patients with recently treated cervical abnormalities must have a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy in order to be eligible
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Neoplasm Cervix HIV-uninfected and infected women (without current AIDS-defining illness) Presence of a cervix Biopsy-proven LSIL disease or recently treated HSIL disease Adherence to combined anti-retrovirals (cART) if HIV infected On continuous antiretrovirals with a cluster of differentiation 4 (CD4) count >200 cells/ml with sustained undetectable viral load for at least 3 months (only for HIV-positive participants) On reliable birth control: combined oral contraceptive pills (OCP), long-acting reversible contraception (LARC), bilateral tubal ligation (BTL) or Depo-Provera (birth control shot) Willing to conform to the study requirements Reliable follow-up and contact information No risk factors for HSIL or microinvasive disease (no colposcopic features of microinvasion, adequate colposcopy and negative endocervical curettage) For women with HSIL only, LEEP completed within 6 weeks preceding initial encounter with study staff and adequate wound healing  Untreated HSIL or invasive features on colposcopy and the biopsy specimen Not adherent to anti-retroviral therapy (cART) (HIV infected participants) CD4 count =<200 cells/ml and detectable viral load within the last 3 months (only for HIV-positive participants) Lactating and pregnant people Patient with irregular cycles (more than once a month) Not on reliable birth control Previous hysterectomy Prior diagnosis of cervical cancer, treated or untreated Inability to provide informed consent Medical condition that interferes with the conduct of the study in the investigator's opinion
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Malignant Female Reproductive System Neoplasm Stage I Cervical Cancer AJCC v8 Stage I Uterine Corpus Cancer AJCC v8 Stage I Vaginal Cancer AJCC v8 Stage I Vulvar Cancer AJCC v8 Stage IA Cervical Cancer AJCC v8 Stage IA Uterine Corpus Cancer AJCC v8 Stage IA Vaginal Cancer AJCC v8 Stage IA Vulvar Cancer AJCC v8 Stage IA1 Cervical Cancer AJCC v8 Stage IA2 Cervical Cancer AJCC v8 Stage IB Cervical Cancer AJCC v8 Stage IB Uterine Corpus Cancer AJCC v8 Stage IB Vaginal Cancer AJCC v8 Stage IB Vulvar Cancer AJCC v8 Stage IB1 Cervical Cancer AJCC v8 Stage IB2 Cervical Cancer AJCC v8 Stage II Cervical Cancer AJCC v8 Stage II Uterine Corpus Cancer AJCC v8 Stage II Vaginal Cancer AJCC v8 Stage II Vulvar Cancer AJCC v8 Stage IIA Cervical Cancer AJCC v8 Stage IIA Vaginal Cancer AJCC v8 Stage IIA1 Cervical Cancer AJCC v8 Stage IIA2 Cervical Cancer AJCC v8 Stage IIB Cervical Cancer AJCC v8 Stage IIB Vaginal Cancer AJCC v8 Stage III Cervical Cancer AJCC v8 Stage III Uterine Corpus Cancer AJCC v8 Stage III Vaginal Cancer AJCC v8 Stage III Vulvar Cancer AJCC v8 Stage IIIA Cervical Cancer AJCC v8 Stage IIIA Uterine Corpus Cancer AJCC v8 Stage IIIA Vulvar Cancer AJCC v8 Stage IIIB Cervical Cancer AJCC v8 Stage IIIB Uterine Corpus Cancer AJCC v8 Stage IIIB Vulvar Cancer AJCC v8 Stage IIIC Uterine Corpus Cancer AJCC v8 Stage IIIC Vulvar Cancer AJCC v8 Stage IIIC1 Uterine Corpus Cancer AJCC v8 Stage IIIC2 Uterine Corpus Cancer AJCC v8 Stage IVA Cervical Cancer AJCC v8 Stage IVA Uterine Corpus Cancer AJCC v8 Stage IVA Vaginal Cancer AJCC v8 Stage IVA Vulvar Cancer AJCC v8 Any patient with endometrial, cervical, vaginal, or vulvar cancer receiving adjuvant external beam radiation or definitive external beam radiation and brachytherapy will be eligible for the study Those receiving concurrent chemotherapy will be eligible Any prior gynecologic surgery is permitted  Patients with metastatic or recurrent disease and patients receiving brachytherapy alone
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Histologically confirmed primary adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, or other histological types carcinoma of the uterine cervix. 2. Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), FIGO 2018 stage IA2 to IIA2. 3. Underwent radical hysterectomy or radiochemotherapy. 4. ECOG Performance Status of 0 or 1  Life expectancy is less than 6 months 2. No prior malignancy 3. ECOG Performance Status of 2 to 5
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Cervix Lesion Cervical Cancer No history of previously treated cervical cancer Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee  Women who are pregnant or nursing
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 1.5-999.0,  Quality of Life Endometrial Cancer Surgery--Complications Gynecologic Cancer Woman over 18 years of age scheduled for primary surgery for histologically verified endometrial cancer (regardless of histological type or degree) tumor clinically restricted to the uterus (presumptive FIGO stage I or II) speaks and reads Swedish capable of completing the questionnaire independently  Clinical or radiological cancer outside the uterus preoperative radio / chemotherapy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-22.0,  Acute Myeloid Leukemia All patients must be enrolled on APEC14B1 and consented to Screening (Part A) prior to enrollment and treatment on AAML1831. Submission of diagnostic specimens must be done according to the Manual of Procedures). Risk stratification will not be possible without the submission of viable samples. Given there are multiple required samples, bone marrow acquisition techniques such as frequent repositioning or performing bilateral bone marrow testing should be considered to avoid insufficient material for required studies. Consider a repeat marrow prior to starting treatment if there is insufficient diagnostic material for the required studies Patients must be less than 22 years of age at the time of study enrollment Patient must be newly diagnosed with de novo AML according to the 2016 World Health Organization (WHO) classification with or without extramedullary disease Patient must have 1 of the following >= 20% bone marrow blasts (obtained within 14 days prior to enrollment) In cases where extensive fibrosis may result in a dry tap, blast count can be obtained from touch imprints or estimated from an adequate bone marrow core biopsy < 20% bone marrow blasts with one or more of the genetic abnormalities (sample obtained within 14 days prior to enrollment) A complete blood count (CBC) documenting the presence of at least 1,000/uL (i.e., a white blood cell [WBC] count >= 10,000/uL with >= 10% blasts or a WBC count of >= 5,000/uL with >= 20% blasts) circulating leukemic cells (blasts) if a bone marrow aspirate or biopsy cannot be performed (performed within 7 days prior to enrollment) ARM C: Patient must be >= 2 years of age at the time of Late Callback ARM C: Patient must have FLT3/ITD allelic ratio > 0.1 as reported by Molecular Oncology  Patients with myeloid neoplasms with germline predisposition are not eligible Fanconi anemia Shwachman Diamond syndrome Patients with constitutional trisomy 21 or with constitutional mosaicism of trisomy 21 Any other known bone marrow failure syndrome Any concurrent malignancy Juvenile myelomonocytic leukemia (JMML) Philadelphia chromosome positive AML Mixed phenotype acute leukemia Acute promyelocytic leukemia
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-50.0,  HIV/AIDS Women who: 1. are confirmed HIV positive based on medical records 2. are women living with HIV infection support group members 3. are ages 20-50 years 4. are no prior cervical cancer screening 5. are no history of invasive cervical cancer 6. are willingness to participate in the study  are not able to speak Chichewa or English 2. self-report currently receiving treatment of a serious mental illness (e.g., schizophrenia and bipolar disorder)